Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the LungImmunotherapy in Treating Patients With Metastatic Breast CancerBiological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast CancerCombination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast CancerDenileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic CancerVaccine Therapy in Treating Patients With Advanced or Metastatic CancerCyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced CancerCombination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerTrastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast CancerSTRIDE - STimulating Immune Response In aDvanced brEast CancerA Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast CancerA Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate CancerVaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerA Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant TherapyTopical Imiquimod and Abraxane in Treating Patients With Advanced Breast CancerChemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast CancerEx Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast CancerEvaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTargeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing SurgeryAnti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerRandomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast CancerVaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyPre-operative Immunotherapy Combination Strategies in Breast CancerBreast Cancer Study of Preoperative Pembrolizumab + RadiationA Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of DarolutamideStudy of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast CancerTo Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid TumorsTriple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerPembrolizumab in Advanced BRCA-mutated Breast CancerNivolumab and Ipilimumab in Treating Patients With Rare TumorsCombination Study of SV-BR-1-GM in Combination With PembrolizumabMPDL3280A-treatment-IST-UMCGSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerSBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCPaclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerImmunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast CancerA Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell SupportImmunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
P1050
P1855
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trialsComparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerpRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epitheliaFatty acid metabolites in rapidly proliferating breast cancerHuman breast cancer tissues contain abundant phosphatidylcholine(36∶1) with high stearoyl-CoA desaturase-1 expressionBisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisCas proteins: dodgy scaffolding in breast cancerThe thyroid, iodine and breast cancerTyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer.Development of bisphosphonates.Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family membersPhenotypic and genetic alterations in mammary stroma: implications for tumour progressionVitamin D and the mammary gland: a review on its role in normal development and breast cancerMicroRNAs and their target gene networks in breast cancerBreast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysisThe NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysisCirculating tumor cells in breast cancer: a tool whose time has come of ageInvasive micropapillary carcinomas arising 42 years after augmentation mammoplasty: a case report and literature reviewEffects of manual lymphatic drainage on breast cancer-related lymphedema: a systematic review and meta-analysis of randomized controlled trialsThe BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancersExpression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patientsS100A7 and the progression of breast cancerInterpretation of microarray data in cancerBRCA2 and homologous recombinationMammary stem cells, self-renewal pathways, and carcinogenesisKey stages in mammary gland development: the cues that regulate ductal branching morphogenesis.The role of oestrogen and progesterone receptors in human mammary development and tumorigenesisFounder populations and their uses for breast cancer genetics.Diet, nutrition, and avoidable cancerLysophosphatidic acid production and action: critical new players in breast cancer initiation and progressionEZH2 methyltransferase and H3K27 methylation in breast cancerEpithelial-mesenchymal transition in cancer: parallels between normal development and tumor progressionIsolated primary breast tuberculosis: report of three cases and review of the literatureAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerEndocrine disruptors and human health--is there a problem? An updateSteroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancerGata-3 and mammary cell fateCaretaker Brca1: keeping the genome in the straight and narrow.Transforming growth factor-beta and breast cancer: IntroductionTransforming growth factor-beta and breast cancer: Mammary gland development.
P921
Q58402915-030A9B89-C8CF-40B7-B1F9-4A612E5C1E6BQ58407330-EDC1643B-9935-4A32-A2ED-5AE0A14952CDQ58407405-AD8C247B-EA1E-47A4-93D3-85861380EC67Q58407412-02524C2A-2D19-41CD-BB82-F0258E37B628Q58407413-47272D64-0964-4C5B-88F6-914B48C0AB99Q58407432-E00C7CCA-2E5E-43EA-B7F8-8CAD93ACBAF9Q58407433-36E05391-8149-43C3-9C4D-BAD16F4A448CQ58407453-8C446455-3B6D-4154-8A01-053AF93607AFQ58407454-456B9239-7A77-430A-8BF4-70B4504EE057Q58407478-779E67CC-EEBF-4A89-AA66-B3C3301C44FFQ58407481-66E00990-3021-4B49-B92B-C5288FB5FA3DQ58407485-0DE7EDA9-C4BA-4315-BFAC-08D093B23426Q58407487-DF241AC0-67A1-4C39-8F91-BB6CE71F6B67Q58407498-AF4C41D6-370E-43E9-87C9-38B4C66C31DCQ58407506-16816287-2C3F-4F45-8DDB-59CFFB733050Q58407512-8BB3C1C3-9C6F-4DC3-8E6E-79E9D6BF8253Q58407527-B677A5B9-348D-47D3-8C6E-EDD8083C4607Q58407530-17323348-35BE-4B19-91DB-B726532D77ADQ58407533-3FC5736C-BDBA-406E-A812-CFFB5C592BE7Q58407574-A27850AB-D8B1-4E12-9628-DE15AA8621DEQ58407579-19FFDC14-38B5-451D-9C19-8D71AFEFBD31Q58407598-497DCB35-7F18-4262-BB07-8E476C0A81EAQ58407606-A18029EB-5981-440B-A6B0-A8CF477D2FBEQ58407612-5200CDF5-F761-424C-AF67-0084BCC6B232Q58407630-6BCB7C98-1F61-488D-9712-4D4F40F88AD0Q58407655-62DCC47B-7003-4E70-ACA7-958520F0D832Q58407660-EE913064-56C3-4D92-A804-C50BFA5E84E8Q58407667-31553282-0413-46A7-8D08-3FE4E3F84893Q58407721-B723CB0D-3C8C-484F-9193-A1E9CC7E9387Q58407726-D4EBE131-2106-4714-ADDE-6F0FE6BFB50EQ58407779-3E68D32F-1771-4649-8F1F-41C78AF73D55Q58407801-315FB47E-0DA3-4951-AB91-35DDD88AB02EQ58407808-666632B4-75C5-4B85-BAEC-210DD3E55BBCQ58407870-120AB7D0-0374-412D-AB63-B23CE8AD5846Q58407879-4D035027-9D82-4195-BF78-C71B5BCF5F96Q58407885-6E160E1B-BAC6-4506-9D57-32C450C17A93Q58407900-0428AB85-CA74-4FBD-A76D-242BA8C37AACQ58407903-352FDC4F-A7E8-4BAE-9A7C-151AED17B110Q58824340-160D6E69-BE86-45D0-8473-4774E5463513Q58844144-8D6FED69-CB7D-4DB3-AFCE-825B6571396F
P1050
Q1149070-28d8d006-478e-c120-0700-4fae6e150ad0Q128581-df695d8d-47ee-303f-70b2-f049ef4692e8Q18553643-03c7d160-422b-d272-1ecd-1e99d703842fQ18975476-de11258c-4849-bc26-41d9-30c16e75a995Q548070-B44554F9-298F-4E83-9572-5D78E645DFB5Q55789471-682320df-456d-fa32-546c-4c38a17a1488Q58833981-a95e1bf9-4daa-5c66-2a24-32f891121988Q58833983-b32e0f79-4d33-e705-15b9-6a4d5cd05641
P279
Q21089763-0C4FF2ED-B4E8-4C7D-AE5E-DA3134A32066Q21089802-5397A230-F781-4F7B-B5FC-825490950FA3Q21090243-FA7E0519-3E64-42BE-A64E-7A5E6969094DQ21090755-CEC6BCFD-B0BF-4125-B3F4-52B76A7514EFQ21090768-C9CBBEE7-E3DA-4D6F-95D8-84F6F4EC9879Q21132670-9F976E27-DF34-4D38-8D13-A97EBAB9EE92Q21146639-885A6C83-C9F8-47A3-A352-4AFB0BE7EF26Q21195176-97CA4870-0D66-463E-9EA8-1D629F9D15D6Q21195187-8525804C-86F6-46BE-8BD9-C52FDFC64A0AQ21195188-CDBADA0F-7AC8-4D81-9FF7-28CF2443A8ABQ21195197-6A6D5F08-C6F7-4FA1-A7B4-DFCD421C6D87Q21195198-A568B398-5406-4A7B-9598-7D868B514F81Q21195200-73B97A5D-662A-466E-96A1-1410744349A5Q21195211-221474E9-1212-4D22-8F96-E8D006AA4B08Q21198839-2838402A-C4FD-49D2-80CF-768B6DAC1428Q21203666-6A8E76CC-DFCD-4C1F-934B-2E366333B301Q21245253-8412F271-D899-411B-9CB0-0A3E1D29950DQ21245585-A9B50B04-3750-46F4-AA1A-3145BC7D1752Q21245604-5CCC1493-8E60-42AB-AEDD-362F02B77581Q21260410-0891D428-5EBE-485A-87A9-68A7418EB032Q21284707-B8495D40-4E26-492E-9A0E-89E4198B6156Q22000741-1F406A6D-3E25-4FEC-A238-07A460F7315EQ24289307-B7E18301-D02A-49D1-9562-31674060781BQ24291786-E14A9B3B-0BFE-4B8C-AE9B-4E0245598C2AQ24529145-E9C4887B-4CF3-40D4-9500-F8550EF74F5FQ24541517-CA6DCC9B-73AF-4F8A-99C6-7EA527CC42F0Q24542480-7DACEB16-2E67-461F-9E84-D825D0462E38Q24544179-0175E836-3808-432E-B6F0-9A6459C7D906Q24554391-57EADAEB-97DE-491C-8C55-41A591508749Q24616764-9FA65DA1-3661-424B-8462-B10171FC22F1Q24633788-FFE96264-3435-4114-9739-04F98E92F900Q24633875-D64E9EF1-B68E-4A4D-91D3-874E1840DB69Q24653966-4EFB3EB5-3A02-4281-8353-9485E5A058B2Q24657308-6FC9E3D4-C559-4A78-84C7-C0A9471D9E2DQ24670574-CF9A9F28-12D9-4504-8934-28830C516DE1Q24680310-4717EA47-D2F3-41B5-8E0C-38F7F07A5C01Q24684456-C4E7500D-4CBC-48F3-8425-1FCC3BC463B0Q24793132-027BE56F-4A2E-4CED-B3C8-2F233D0D6A93Q24793174-603F62E0-21E8-4C5F-A951-BFCE86D91644Q24793194-7F43D5DA-D400-49EC-8C87-1CC70E3C147A
P921
description
tumors or cancer of the human breast
@en
name
breast neoplasm
@en
tumeur du sein
@fr
type
label
breast neoplasm
@en
tumeur du sein
@fr
altLabel
Breast Neoplasms
@en
prefLabel
breast neoplasm
@en
tumeur du sein
@fr
P486
P1995
P31
P486
P672
C04.588.180
C17.800.090.500